All News

search bar

How Online Searches Reveal Patient Needs

d Bella Mehta, MBBS, MS

Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.

Read Article
#0322🔬 Myocarditis in Myositis(IIM) 📊 26% new IIM pt had myocarditis (ESC,Lake Louise) 💥 Anti-Ku most common MSA 💥Myocarditis a/w ⬆️heart failure, arrhythmia (43 v 6%;p=0.02) 🎯 Myocarditis🟰poor outcomes 🎯Cardiac MRI🟰earlier detection #ACR24 @RheumNow @JuliePaikMD https://t.co/yz0f2ozFVL

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
"If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight" -P. Merkel at UPA plenary session #ACR24 @RheumNow

Mike Putman EBRheum ( View Tweet)

How to Master ACR Meetings https://t.co/ATbOYbatOy https://t.co/j1oRBbhWY2

Links:

Dr. John Cush RheumNow ( View Tweet)

Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#obesity causes a lot of diseases including #arthritis. How? ⬆️ IL-6 ⬆️ leptin ⬆️ TNF-a @RheumNow #ACR24 @rheumarhyme https://t.co/qeqTZUOEZy

Links:

sheila RHEUMarampa ( View Tweet)
The Plants for Joints RA continuation made it to #ACR24! whole-food plant-based diet, exercise, sleep/stress Rx (added on to usual RA care i.e. DMARDs) Gains made during program were sustained, can't undersell lifestyle as part of the overall picture! #ACR24 ABST0530 @RheumNow https://t.co/XSLIwYitpH https://t.co/RfiTX8Z6ff

Links:

David Liew drdavidliew ( View Tweet)
The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Want to lose weight naturally? Eat your veggies and protein first, and the carbs last— this reduces the post-prandial glucose, insulin and raises GLP-1 - Dr Aronne #ACR24 @RheumNow https://t.co/cRVRzRTljT

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Dactylitis management in PsA: Acute: pain and swelling Chronic: painless swelling Broad ddx No role for LEF or SSZ #ReviewCourse #ACR24 @RheumNow https://t.co/KZXv1UvhXn

Links:

Adela Castro AdelaCastro222 ( View Tweet)

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

Links:

Eric Dein ericdeinmd ( View Tweet)
Great summary of treatment choices in PsA: 1. Identify domain involved 2. Identify comorbidities/pt preferences 3. Still unmet needs for ttx in inflammatory eye disease #ACR24 @rheumnow https://t.co/1WMnkDYvip

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV

Links:

Richard Conway RichardPAConway ( View Tweet)
What agent to pick after a TNFi has failed: another TNFi or a non-TNFi? Would a TNFi drug conc help (i.e. if low, increased clearance due to secondary failure)? In this RCT @maartenskliniek, this TDM approach was no better than random selection. Argh #ACR24 ABST0533 @RheumNow https://t.co/3h8o4ARZG3

Links:

David Liew drdavidliew ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years. Usually, seroneg RA means seroneg RA! #ACR24 @MyasoedovaElena ABST0458 @RheumNow https://t.co/hErZVfs08k

Links:

David Liew drdavidliew ( View Tweet)
❓What factors influence patient participation in rheumatology #ClinicalTrials? 📌 Come to poster 0366 to find out! 👨🏻‍⚕️ @KKouranloo & @chriswincup report results from a UK study, showing marked differences by ethnicity & RMD @RheumNow Ab0366 #ACR24 https://t.co/kAqGJmNiPt

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi

Links:

David Liew drdavidliew ( View Tweet)
Spatial Proteomics study for TEN Marked enrichment of type I and II interferon and STAT1 activation Pathways suggests benefit for JAKi in this condition Clinical response in case photos, suggests benefit of pursuing clinical trial Year in Review #ACR24 Bridges @RheumNow https://t.co/K34lbnenRH

Links:

Eric Dein ericdeinmd ( View Tweet)
Have you ever tried giving Semaglutide in addressing weight loss among your patients with #osteoarthritis and #obesity? @RheumNow #ACR

sheila RHEUMarampa ( View Tweet)

Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5

Links:

David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×